At Leoplex, we offer product diversification which means that we split investments into different financial markets, of which Canabis Stock happens to be one of them and we have experienced high profit margins due to our precise ability to analyze the market through our advanced A.I Technology. Therefore we have stable and long-term results and our algorithms guide us towards profitable paths.
WHAT IS CANABIS?
Canabis is a plant that consists of two primary chemical compounds which are of great importance in both the medical and financial sector. Delta-9 tetrahydrocannabinol (THC) which is one of the chemical compounds found in canabis is the primary psychoactive ingredient in canabis, While Cannabidiol (CBD) is another important cannabinoid that has been found to possess therapeutic benefits.
These two ingredients have been at the forefront of a battle over canabis. The United States, along with many other countries around the world, prohibit the use of marijuana at the federal level, primarily because of the mind-altering effects and potentially addictive attributes of THC. However, the potential therapeutic benefits of CBD have led 30 U.S. states and countries, including Canada and Germany, to legalize medical marijuana. In addition, nine U.S. states and the District of Columbia also now allow the legal recreational use of marijuana. The spread of marijuana legalization has created a blossoming industry. Businesses have popped up to service every part of the growing industry, from cultivating and growing cannabis (or providing services to the growers), to distribution and retail marketing, and even to biotech development of cannabinoid-based prescription drugs.
This growth potential is the most compelling reason to consider investing in canabis stocks. Arcview Market Research and BDS Analytics project that Canadian marijuana sales will jump to $11.5 billion by 2025. That's a compound annual growth rate of more than 55%. You might also be aware of predictions about how large the cannabis industry could become, including a recent projection that the U.S. marijuana market could reach $32 billion by 2025. These projections have Increased the numbers of investors who have bought shares of canabis stocks.
Germany legalized medical marijuana in 2017. The country's cannabis market could approach $5.6 billion by 2025, according to Arcview and BDS Analytics. Germany is not only the biggest international marijuana market outside of North America but also the fastest-growing marijuana market in the world. Overall, there is a possibility that the global marijuana market will more than triple from 2023 to the end of 2024.
Many companies in the cannabis industry have opted to "go public," making their shares available for purchase on public stock markets, to raise cash to fuel additional growth. This growth potential is the most compelling reason to consider investing in canabis stocks. Investors who accurately pick these winners should be set for some fantastic returns over the next few years.
CANABIS STOCK MARKET
The canabis industry at large is expected to generate upwards of $15 billion in added annual sales. This comes atop what growers were already bringing in via medical weed sales and exports to foreign countries. This longawaited legalization is what's been responsible for sending canabis or pot stocks through the roof for years. The following five marijuana stocks, listed in ascending order, are hands-down the industry's top performers in that time span.
1. Namaste Technologies: Up 6,750% However, more than doubling up the second-best performer since the beginning of 2016 is small-cap Namaste Technologies (NASDAQOTH:NXTTF). Having finished 2015 at just $0.02 per share, Namaste has since gained a brisk 6,750% as its telemedicine app and vaporizer business has grown in size. Since its launch, NamasteMD has already attracted more than 17,000 patients.
2. Cronos Group: Up 3,313% (on the Canadian exchange) Among the big boys, no canabis stock has performed better than Cronos Group(NASDAQ:CRON), which, according to its Canadian-listed shares, are up better than 3,300% since the beginning of 2016. Cronos Group has likely found support from investors, given that it's on track to be a top-10 producer.
3. MariMed: Up 3,093% Perhaps one of the more surprising names you'll find on this list is Massachusettsbased cannabis consulting and grow-facility operator MariMed (NASDAQOTH:MRMD). It's come a long way from its $0.15 share price at the end of 2015, and now sits nearly 3,100% higher.
4. Canopy Growth Corp.: Up 2,602% (on the Canadian exchange) Speaking of showing up for investors, Canopy Growth Corp. (NYSE:CGC) has kicked butt and taken names since the beginning of 2016. The first Canadian marijuana stock to list on the NYSE has seen its shares rise by a brisk 2,602% in roughly 34 months, according to its Canadian-listed shares. Canopy Growth is probably going to slide in behind Aurora Cannabis as the nation's second-largest producer. Canopy Growth's Tweed brand is arguably the most recognizable throughout Canada, and Constellation Brands' $4 billion investment in Canopy Growth Corp.
5. Aurora Cannabis: Up 1,571% Although it's a company I might rail on for its acquisition binges and subsequent ballooning of its outstanding share count, grower Aurora Cannabis (NYSE:ACB) has done well for itself and shareholders with a 1,571% gain since 2016 began. Aurora Cannabis, which recently uplisted to the New York Stock Exchange (NYSE), looks to have the inside track to the peak production crown.
The financial world continually evolves, embracing new innovations with complexity and absorbing the new regulations. As the pace of change increases, Our team with the aid of Artificial intelligence works to help clients overcome the challenges of the market technicalities thereby ensuring that our investors capitalize on the these highly complex, volatile and highly profitable markets, without any expertise of their own.
